|
|
|
|
|
|
|
|
|
|
|
|
|
23.06.25 - 12:21
|
Final Countdown: Judge Set To Rule On Controversial Sale Of 23andMe′s Massive Pool Of Genetic Data (ZeroHedge)
|
|
|
Final Countdown: Judge Set To Rule On Controversial Sale Of 23andMe's Massive Pool Of Genetic Data
A bankruptcy judge is weighing the proposed sale of 23andMe's assets—including a vast pool of genetic data of millions of Americans—to co-founder Anne Wojcicki and the nonprofit TTAM Research Institute on Friday.
Bloomberg reports that Judge Brian C. Walsh of the U.S. Bankruptcy Court for the Eastern District of Missouri heard hours of arguments over the sale of 23andMe's genetic data of 15 million customers. Wojcicki and the nonprofit TTAM Research Institute won an auction earlier this month over biotech firm Regeneron for the massive genetic database of Americans.
While the deal is structured as a Chapter 11 asset transfer to a newly formed affiliate (staffed by current management), multiple U.S. states—including California and Texas—have raised serious objections, arguing the sale violates state privacy laws and lacks required user consent.
Who is TTAM?
Attorneys representing...
|
|
|
|
|
|
|
|
|
|
|
|
|
18.06.25 - 13:06
|
Actio Biosciences Secures $66 Million Series B Financing to Advance Genetics-Driven Pipeline of Small Molecule Therapeutics for Rare and Common Diseases (Business Wire)
|
|
|
Financing co-led by Regeneron Ventures and Deerfield Management will support advancement of lead programs, ABS-1230 and ABS-0871
Phase 1 trial initiation expected in second half 2025 for ABS-1230, a KCNT1 inhibitor for the treatment of KCNT1-related epilepsy; program granted rare pediatric and orphan drug designations by FDA
Enrollment ongoing in Phase 1 trial for ABS-0871, a TRPV4 inhibitor for the treatment of Charcot-Marie-Tooth disease type 2CSAN DIEGO--(BUSINESS WIRE)--Actio Biosciences, a clinical-stage biotechnology company leveraging a novel approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases, today announced the closing of a $66 million Series B financing. New investor Regeneron Ventures and current investor Deerfield Management co-led the financing, with participation from existing investors Canaan, Droia Ventures and Euclidean Capital.
Actio's pipeline is led by ABS-1230, a KCNT1 inhibitor for the treatm...
|
|
|
|
|
16.06.25 - 17:06
|
23andMe′s founder wins bid to regain control of bankrupt DNA testing firm (The Guardian)
|
|
|
Anne Wojcicki made $305m bid for firm, which has lost customers since declaring bankruptcy, with backing of Fortune 500 company 23andMe's former CEO is set to regain control of the genetic testing company after a $305m bid from a non-profit she controls topped a pharmaceutical company's offer for it in a bankruptcy auction.Last month, Regeneron Pharmaceuticals agreed to buy the firm for $256m, topping a $146m bid from Anne Wojcicki and the non-profit TTAM Research Institute. The larger offer prompted Wojcicki to raise her own with the backing of a Fortune 500 company, according to the former executive. The deal is expected to close in the coming weeks after a court hearing currently scheduled for 17 June, the company said on Friday. Continue reading......
|
|
|
|
|
|
|
|
|
|
|
|
|
11.06.25 - 17:06
|
Regeneron Pharmaceuticals Aktie: Massives Comeback-Potenzial! (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Regeneron Pharmaceuticals-Aktienanalyse von J.P. Morgan Securities:
JPMorgan habe laut einer am Montag veröffentlichten Studie das Kursziel für die Aktie von Regeneron Pharmaceuticals Inc. (ISIN: US75886F1075, WKN: 881535, Ticker-Symbol: RGO, NASDAQ-Symbol: REGN) von 950 USD auf 800 USD gesenkt, halte jedoch weiter an einem "overweight"-Rating fest. [mehr]...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
